InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.67
(
0.00%
)
US TECH 100
17,569.20
(
-0.19%
)
Dow Jones
39,056.39
(
0.44%
)
Brent Oil
84.02
(
0.54%
)
Bitcoin
60,978.41
(
-0.34%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 351

Friday, 09/14/2018 6:59:29 PM

Friday, September 14, 2018 6:59:29 PM

Post# of 438
DFFN will be the first Biotech to be sanctioned by the FDA to conduct a trial in the back of ambulances.

DFFN is planning a Ph2 study for its TSC molecule to treat Acute Stroke. The global stroke market has a TAM of $36B

TSC is also being studied to speed diffusion of drug thru solid tumors. DFFN has programs in Glioblastoma, Pancreatic Cancer & Brain Metastases.

Cash runway extends thru H2/19; but, Ph3 study(ies) will require a partnership or significant dilutive financing.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up